Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile : cost-effectiveness analysis and a mixed treatment comparison

Simple item page
dc.contributor.authorVargas, C.
dc.contributor.authorBalmaceda, Carlos
dc.contributor.authorRodrĂ­guez, F.
dc.contributor.authorRojas, R.
dc.contributor.authorGiglio, A.
dc.contributor.authorEspinoza SepĂșlveda, Manuel Antonio
dc.date.accessioned2021-05-31T03:43:56Z
dc.date.available2021-05-31T03:43:56Z
dc.date.issued2019
dc.format.extent9 pĂĄginas
dc.fuente.origenConveris
dc.identifier.doi10.1080/14737167.2019.1580572
dc.identifier.issn1473-7167
dc.identifier.urihttps://doi.org/10.1080/14737167.2019.1580572
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/59878
dc.issue.numeroNo. 5
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final617
dc.pagina.inicio609
dc.revistaExpert Review of Pharmacoeconomics and Outcomes Researches_ES
dc.rightsacceso restringido
dc.titleEconomic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile : cost-effectiveness analysis and a mixed treatment comparisones_ES
dc.typeartĂ­culo
sipa.codpersvinculados10720
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Economic evaluation of sunitinib versus pazopanib and best supportive care fo.pdf
Size:
3.16 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
ArtĂ­culos de revistas